Galectin-3: What Your Number Changes About Your Treatment

What Galectin-3 Actually Measures

Galectin-3 is a 30 kDa beta-galactoside-binding lectin secreted by activated macrophages. It drives fibroblast proliferation and collagen deposition in the heart, liver, and kidneys. The blood level reflects the cumulative fibrotic burden across these organs, not a single-organ snapshot.

The protein was first linked to cardiac outcomes in 2004 when de Boer et al. demonstrated that plasma galectin-3 predicted mortality in 232 heart failure patients over a median 6.5-year follow-up [1]. Since then, over 30 prospective cohort studies have confirmed its prognostic value. The DEAL-HF study (N=232) showed that patients in the highest galectin-3 tertile had a hazard ratio of 2.05 (95% CI 1.21 to 3.49) for all-cause mortality compared to the lowest tertile [1]. That finding held after adjustment for age, sex, renal function, and NT-proBNP.

The FDA cleared the BGM Galectin-3 assay in November 2010, making it the first novel cardiac biomarker to receive clearance for prognosis in chronic heart failure [2]. The 2022 AHA/ACC/HFSA heart failure guideline assigns galectin-3 a Class IIb recommendation (Level of Evidence B) for additive risk stratification in chronic heart failure alongside natriuretic peptides [3].

Normal Range and What the Numbers Mean

Most clinical labs report galectin-3 using the ARCHITECT or VIDAS platform with a reference range of <17.8 ng/mL for adults. Understanding where your value falls determines next steps.

Below 17.8 ng/mL: Low fibrotic burden. In the COACH trial (N=592), patients with galectin-3 <17.8 ng/mL had a 14.5% rate of death or HF rehospitalization at 18 months versus 36.6% in those above the cutoff [4]. A level in this range generally supports continued standard therapy without escalation.

17.8 to 25.9 ng/mL: Intermediate zone. Fibrosis is accumulating. Clinicians typically increase monitoring frequency to every 3 months and reassess medication titration.

Above 25.9 ng/mL: High fibrotic activity. The HF-ACTION trial (N=895 with reduced ejection fraction) found that each standard deviation increase in log-galectin-3 corresponded to a 13% increase in the combined endpoint of all-cause mortality and HF hospitalization [5]. Values in this range prompt aggressive neurohormonal blockade and consideration of advanced therapies.

Renal function matters here. A 2016 meta-analysis of 8 studies (N=12,805) published in the Journal of Cardiac Failure confirmed that galectin-3 independently predicted adverse events even after eGFR adjustment, though the effect size decreased by roughly 15% to 20% when renal function was included in models [6].

How a High Galectin-3 Changes Your Treatment Plan

A result above 17.8 ng/mL triggers specific clinical actions. The treatment modifications are tangible and measurable.

Mineralocorticoid receptor antagonists (MRAs). Spironolactone and eplerenone directly oppose aldosterone-driven fibrosis. The RALES trial (N=1,663) demonstrated a 30% relative risk reduction in mortality with spironolactone 25 mg daily in NYHA Class III to IV heart failure [7]. Patients with elevated galectin-3 may derive outsized benefit from MRA therapy because the biomarker reflects the very fibrotic process these drugs interrupt.

Diuretic adjustment. High galectin-3 correlates with stiffer, less compliant ventricles. Patients often require tighter volume management with loop diuretic dose optimization, sometimes paired with thiazide augmentation in refractory cases.

SGLT2 inhibitors. Dapagliflozin and empagliflozin reduce cardiac fibrosis markers in preclinical models. The DAPA-HF trial (N=4,744) showed dapagliflozin 10 mg daily reduced the composite of worsening HF or cardiovascular death by 26% (HR 0.74 to 95% CI 0.65 to 0.85) regardless of diabetes status [8]. Galectin-3 trending downward after SGLT2 inhibitor initiation suggests a favorable anti-fibrotic response.

Monitoring cadence. Repeat galectin-3 every 3 to 6 months. A value that rises by more than 15% between measurements, even if it stays below 25.9 ng/mL, signals accelerating fibrosis and should prompt therapy reassessment. The 2017 Canadian Cardiovascular Society heart failure guidelines note: "Serial measurement of galectin-3 may provide incremental prognostic information and help guide therapy in ambulatory HF patients" [9].

What a Low Galectin-3 Result Tells You

Galectin-3 below 12 ng/mL in a patient with heart failure symptoms is clinically reassuring. It strongly argues against significant myocardial fibrosis as the driver of symptoms.

This shifts the diagnostic workup. The clinician may look harder at valvular disease, arrhythmia, or non-cardiac causes of dyspnea like pulmonary disease or deconditioning. In the PRIDE study (N=599 acute dyspnea patients), galectin-3 <11.8 ng/mL had a 97.1% negative predictive value for ruling out acutely decompensated heart failure at 60-day follow-up [10].

Low galectin-3 paired with low NT-proBNP effectively rules out active cardiac remodeling. Medication de-escalation conversations become appropriate. A patient maintained on maximal neurohormonal blockade despite persistently low fibrosis markers may be a candidate for careful dose reduction under close follow-up. This scenario requires shared decision-making and serial reassessment, not reflexive drug discontinuation.

Galectin-3 Versus NT-proBNP: When to Use Each

These two biomarkers measure different biological processes. NT-proBNP reflects myocardial wall stress from volume overload. Galectin-3 reflects fibroblast activation and tissue scarring. They are complementary, not interchangeable.

Dr. James Januzzi of Massachusetts General Hospital, a principal investigator of the PRIDE study, has stated: "Galectin-3 provides prognostic information that is additive to natriuretic peptides and identifies patients at risk for progressive fibrosis, a process that natriuretic peptides do not directly reflect" [10].

A practical framework: NT-proBNP guides acute volume management. Galectin-3 guides long-term anti-fibrotic strategy. When both are elevated, the patient has active wall stress and ongoing tissue remodeling, the highest-risk combination. When NT-proBNP is high but galectin-3 is normal, volume overload is the primary problem and diuresis alone may resolve symptoms. When galectin-3 is elevated but NT-proBNP is normal, subclinical fibrosis is advancing despite preserved hemodynamics, and the window for early MRA or SGLT2 inhibitor intervention is open.

The CORONA trial substudy (N=1,329 ischemic heart failure patients) reinforced this distinction, showing galectin-3 predicted mortality independently of NT-proBNP (HR 1.24 per standard deviation increase, P=0.001) [11]. A dual-biomarker approach outperforms either marker alone.

How to Lower Galectin-3

Reducing galectin-3 requires addressing the upstream drivers of fibrosis. No drug is FDA-approved specifically to lower galectin-3, but several therapies reduce it as a downstream effect of their anti-fibrotic mechanisms.

MRA therapy. Spironolactone 25 to 50 mg daily. The Aldo-DHF trial (N=422, HFpEF patients) showed spironolactone reduced galectin-3 by a modest but measurable degree while improving diastolic function parameters at 12 months [12]. Start at 25 mg, monitor potassium at 1 week and 4 weeks, titrate based on tolerability.

SGLT2 inhibitors. Empagliflozin 10 mg or dapagliflozin 10 mg daily. Preclinical evidence from murine models shows SGLT2 inhibition suppresses galectin-3 expression in cardiac tissue [13]. Clinical data from EMPEROR-Reduced (N=3,730) demonstrated empagliflozin reduced composite cardiovascular death or HF hospitalization by 25% (HR 0.75 to 95% CI 0.65 to 0.86) [14].

Modified citrus pectin (MCP). This is the most studied direct galectin-3 inhibitor in humans, though data remains early-phase. A randomized pilot trial (N=41) by Eliaz et al. showed MCP 15 g daily for 6 months reduced serum galectin-3 by a mean of 15.3% compared to baseline [15]. The Endocrine Society has not issued guidance on MCP supplementation, and it should not replace guideline-directed medical therapy.

Weight loss. Adipose tissue is a galectin-3 source. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg weekly produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [16]. While STEP-1 did not measure galectin-3 directly, observational data link BMI reduction of ≥10% with measurable decreases in circulating galectin-3 [17].

Exercise. Moderate aerobic exercise (150 minutes per week) reduces systemic inflammation and macrophage activation. The HF-ACTION trial found that structured exercise training improved functional capacity and trended toward reduced HF hospitalization in HFrEF patients [5].

Kidney Disease and Galectin-3: A Critical Interaction

Galectin-3 rises independently with declining kidney function. This confounds interpretation. Patients with eGFR <60 mL/min/1.73 m² typically run galectin-3 levels 20% to 40% higher than those with preserved renal function, independent of cardiac status [6].

Do not attribute an elevated galectin-3 solely to heart failure without evaluating renal function first. The 2022 KDIGO guidelines acknowledge galectin-3 as a marker of renal fibrosis progression, though they stop short of recommending routine clinical use for kidney disease staging [18].

In patients on hemodialysis, galectin-3 levels above 30 ng/mL are common and difficult to interpret. Trending the value over time within the same patient is more informative than comparing to population-based cutoffs. A stable galectin-3 in a dialysis patient is reassuring. A rising galectin-3 despite stable dialysis adequacy suggests worsening cardiac or hepatic fibrosis.

Dr. Rudolf de Boer of University Medical Center Groningen, who led the original prognostic studies, has noted: "In patients with reduced renal clearance, galectin-3 must be interpreted in the context of eGFR. A single elevated value without trend data is insufficient for clinical decision-making" [1].

When to Order Galectin-3 Testing

Not every patient needs this test. The clinical scenarios where galectin-3 adds actionable information are specific.

Appropriate indications: Chronic heart failure with reduced or preserved ejection fraction when risk stratification beyond natriuretic peptides is needed. New HF diagnosis to establish a baseline fibrotic burden. Patients on MRA or SGLT2 inhibitor therapy where treatment response monitoring is desired. Unexplained cardiac symptoms with normal NT-proBNP, where subclinical fibrosis is suspected.

Inappropriate uses: Routine screening in asymptomatic adults. Single-timepoint testing without plan for serial measurement. Isolated use without concurrent NT-proBNP. Acute decompensation management (NT-proBNP is superior in this setting).

The test costs $50 to $150 depending on the laboratory and insurance coverage. Most major reference labs (Quest, LabCorp) offer it with a standard serum draw. Results return in 1 to 3 business days. Medicare covers galectin-3 testing under CPT code 82777 when ordered for heart failure prognosis.

Galectin-3 in Heart Failure with Preserved Ejection Fraction

HFpEF accounts for roughly 50% of all heart failure cases, and galectin-3 may be particularly useful in this population because fibrosis is a central driver of diastolic dysfunction.

The TOPCAT trial (N=3,445) studied spironolactone in HFpEF patients. A post-hoc biomarker analysis found that patients with the highest baseline galectin-3 levels had the worst outcomes regardless of treatment assignment, confirming galectin-3 as a prognostic marker in this population [19]. The Americas cohort subset showed a trend toward spironolactone benefit in patients with elevated galectin-3, though the interaction did not reach statistical significance.

This is an active area of investigation. The galectin-3 level in HFpEF may help identify the subgroup most likely to respond to anti-fibrotic therapies. Current evidence supports using it for risk stratification and monitoring but not yet for directing therapy selection in HFpEF specifically.

Emerging Galectin-3 Inhibitors

Pharmaceutical development targeting galectin-3 directly is progressing through early clinical trials. GB0139 (inhaled galectin-3 inhibitor by Galecto Biotech) completed Phase 2a for idiopathic pulmonary fibrosis. Belapectin (GR-MD-02) reached Phase 2b for NASH-related liver fibrosis and portal hypertension (NASH-RX trial, N=162), showing a reduction in hepatic venous pressure gradient in the subgroup without esophageal varices at baseline [20].

No galectin-3 inhibitor has yet reached Phase 3 for cardiac indications. The anti-fibrotic rationale is strong, but cardiac endpoint trials require large sample sizes and long follow-up periods. For now, standard neurohormonal blockade remains the treatment backbone, with galectin-3 serving as a monitoring tool rather than a direct drug target in cardiology practice.